Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (3800)	10/22/2014 11:29:13 AM
From: ItsAllCyclical	Read Replies (1) \| Respond to of 8288

Agree. Bought a small stake today and will likely add some on dips. More of a sleeper position. Didn't want to buy ahead of earnings. Could see it getting back into the 50's over the next year with div income added in that's a decent return. Don't trust straight up nature of markets and hard to believe ebola won't make it into the headlines again so thinking there will be more dips to buy stocks like this.

To: The Ox who wrote (3800)	12/10/2014 4:25:54 PM
From: The Ox	Respond to of 8288

As soon as GSK started climbing, it got shot down. Here's the latest: BofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Underperform with a price target of $45.50 (from $54.00) saying they expected the EPS downgrade cycle to continue. Analyst Graham Parry notes the downgrade was driven 8-25% cuts to their EPS forecasts following a detailed review of near-term margin pressures, lower long-term expectations for new respiratory products and reduced buybacks given lower earnings. "We believe GSK’s EPS downgrade cycle has not ended given our FY15/16 forecasts are c10% below consensus and our lower EPS increases our concern over long-term dividend sustainability," Parry said. "We see few pipeline catalysts and limited strategic options as an offset beyond the proposed ViiV minority IPO."